Paige
@eppolmo.bsky.social
MBC•ILC•PATIENT•ADVOCATE•SEARCHING FOR BETTER #bcsm #oncsky #cansky
Sometimes less is more.
“When choosing cancer therapies, people should not have to choose between being alive & living”
Toxicity minimizing language ("safe” & “tolerable”) are subjective & can downplay QOL limiting side effects from treatment.
🚨New @ascocancer.bsky.social Podcast is live today!
@coffeemommy.bsky.social
Toxicity minimizing language ("safe” & “tolerable”) are subjective & can downplay QOL limiting side effects from treatment.
🚨New @ascocancer.bsky.social Podcast is live today!
@coffeemommy.bsky.social
Incomplete Reporting and Toxicity-Minimizing Language in Oncology | Podcast | ASCO Publications
There is often a disconnect in toxicity assessment between what is reported on clinical trials as being “well tolerated” and the lived experience of taking a treatment for patients. Toxicity minimizin...
ascopubs.org
July 29, 2025 at 1:13 AM
Sometimes less is more.
Thread!
These moves at NIH should alarm everyone. Not only because they are targeted at grants looking to address disparities. 1/6
www.nature.com/articles/d41...
www.nature.com/articles/d41...
Exclusive: NIH to terminate hundreds of active research grants
Studies that touch on LGBT+ health, gender identity and DEI in the biomedical workforce could be terminated, according to documents obtained by Nature.
www.nature.com
March 7, 2025 at 1:24 PM
Thread!
Reposted by Paige
Good news for #lobular: @theaacr.bsky.social #AACR25 now has an Advances session on ILC!
AOS12 - New Findings in Invasive Lobular Breast Cancer: Histology Matters
www.abstractsonline.com/pp8/#!/20273...
Excited to be the intermission btw Steffi Oesterreich & Christina Curtis 😅. See you in Chicago!
AOS12 - New Findings in Invasive Lobular Breast Cancer: Histology Matters
www.abstractsonline.com/pp8/#!/20273...
Excited to be the intermission btw Steffi Oesterreich & Christina Curtis 😅. See you in Chicago!
Program Planner
www.abstractsonline.com
March 3, 2025 at 8:41 PM
Good news for #lobular: @theaacr.bsky.social #AACR25 now has an Advances session on ILC!
AOS12 - New Findings in Invasive Lobular Breast Cancer: Histology Matters
www.abstractsonline.com/pp8/#!/20273...
Excited to be the intermission btw Steffi Oesterreich & Christina Curtis 😅. See you in Chicago!
AOS12 - New Findings in Invasive Lobular Breast Cancer: Histology Matters
www.abstractsonline.com/pp8/#!/20273...
Excited to be the intermission btw Steffi Oesterreich & Christina Curtis 😅. See you in Chicago!
Reposted by Paige
The ordinarily cautious and conservative ABA is blowing the whistle: The break-the-glass moment has arrived.
www.americanbar.org/news/abanews...
www.americanbar.org/news/abanews...
February 11, 2025 at 2:11 PM
The ordinarily cautious and conservative ABA is blowing the whistle: The break-the-glass moment has arrived.
www.americanbar.org/news/abanews...
www.americanbar.org/news/abanews...
Reposted by Paige
When Elon was a kid, survival for ALL, the most common childhood cancer, was <10%
Now it’s >90% due to funded collaboratives (high indirect costs) whose work ultimately SAVES THOUSANDS OF LIVES EVERY YEAR.
For other cancers there’s still so much progress to be made.
I think it’s worth it.
Now it’s >90% due to funded collaboratives (high indirect costs) whose work ultimately SAVES THOUSANDS OF LIVES EVERY YEAR.
For other cancers there’s still so much progress to be made.
I think it’s worth it.
February 8, 2025 at 11:04 PM
When Elon was a kid, survival for ALL, the most common childhood cancer, was <10%
Now it’s >90% due to funded collaboratives (high indirect costs) whose work ultimately SAVES THOUSANDS OF LIVES EVERY YEAR.
For other cancers there’s still so much progress to be made.
I think it’s worth it.
Now it’s >90% due to funded collaboratives (high indirect costs) whose work ultimately SAVES THOUSANDS OF LIVES EVERY YEAR.
For other cancers there’s still so much progress to be made.
I think it’s worth it.
Reposted by Paige
Contact your representatives- make sure they know what the impact of this is. #NIHsky #cansky #oncsky #IDsky
⏱️ The next cancer cure is on hold.
@NIH grants invest in future science gains that pay back for our citizens at a rate of more than 2:1 in economic activity.
We are losing the battle for discovery.
@NIH grants invest in future science gains that pay back for our citizens at a rate of more than 2:1 in economic activity.
We are losing the battle for discovery.
Trump hits NIH with ‘devastating’ freezes on meetings, travel, communications, and hiring
Researchers facing
www.science.org
January 23, 2025 at 11:17 AM
Reposted by Paige
Don't miss this recent review outlining practical treatment strategies and novel therapies in the PI3K/AKT/mTOR pathway in HR+/HER2- advanced #BreastCancer
🔓 pubmed.ncbi.nlm.nih.gov/39674130/
@antgiordanomd.bsky.social @drtimothyerick.bsky.social @stolaney1.bsky.social @drsarahsammons.bsky.social
🔓 pubmed.ncbi.nlm.nih.gov/39674130/
@antgiordanomd.bsky.social @drtimothyerick.bsky.social @stolaney1.bsky.social @drsarahsammons.bsky.social
January 15, 2025 at 3:59 PM
Don't miss this recent review outlining practical treatment strategies and novel therapies in the PI3K/AKT/mTOR pathway in HR+/HER2- advanced #BreastCancer
🔓 pubmed.ncbi.nlm.nih.gov/39674130/
@antgiordanomd.bsky.social @drtimothyerick.bsky.social @stolaney1.bsky.social @drsarahsammons.bsky.social
🔓 pubmed.ncbi.nlm.nih.gov/39674130/
@antgiordanomd.bsky.social @drtimothyerick.bsky.social @stolaney1.bsky.social @drsarahsammons.bsky.social
Reposted by Paige
Now online in JCO #postMonarch
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial
PURPOSECyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET)
are the standard first-line treatment for hormone receptor-positive (HR+), human epidermal
growth factor re...
ascopubs.org
December 22, 2024 at 10:31 PM
Now online in JCO #postMonarch
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky
Reposted by Paige
I'm excited to see ELBCC join the blue space! 🎉 Check out the terrific presentations from the #ILCSymposium 2024 in Leuven, which are all now available: youtube.com/@elbcc.europ..
December 21, 2024 at 9:44 AM
I'm excited to see ELBCC join the blue space! 🎉 Check out the terrific presentations from the #ILCSymposium 2024 in Leuven, which are all now available: youtube.com/@elbcc.europ..
Reposted by Paige
Did you miss #SABCS24 last week? No worries! Here's my @fredhutch.bsky.social SABCS24 wrap story w/insights into #cancer treatments & #cannabis; #ctDNA; #obesity & #epigenetics, #FES-PET & much more. #cansky #oncocsky #medsky #bcsm @thankscancer.bsky.social
www.fredhutch.org/en/news/cent...
www.fredhutch.org/en/news/cent...
What’s new in breast cancer research? SABCS24 looks at ctDNA, AI and ‘right-sizing’ treatment
More than 11,000 researchers, clinicians, patient advocates and drugmakers gathered last week at the San Antonio Breast Cancer Symposium to share the latest treatments, tricks and tools to take down b...
www.fredhutch.org
December 20, 2024 at 9:01 PM
Did you miss #SABCS24 last week? No worries! Here's my @fredhutch.bsky.social SABCS24 wrap story w/insights into #cancer treatments & #cannabis; #ctDNA; #obesity & #epigenetics, #FES-PET & much more. #cansky #oncocsky #medsky #bcsm @thankscancer.bsky.social
www.fredhutch.org/en/news/cent...
www.fredhutch.org/en/news/cent...
Reposted by Paige
Wrapping up another fantastic #SABCS!
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
December 13, 2024 at 8:08 PM
Wrapping up another fantastic #SABCS!
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Reposted by Paige
Dr Kaelin gave a very thought provoking talk.
He argues single agent therapies will never cure cancer due to resistance.
Our chance is cure will come with multiple non-cross resistant therapies, challenging current paradigms.
#bcsm
He argues single agent therapies will never cure cancer due to resistance.
Our chance is cure will come with multiple non-cross resistant therapies, challenging current paradigms.
#bcsm
December 13, 2024 at 2:08 PM
Dr Kaelin gave a very thought provoking talk.
He argues single agent therapies will never cure cancer due to resistance.
Our chance is cure will come with multiple non-cross resistant therapies, challenging current paradigms.
#bcsm
He argues single agent therapies will never cure cancer due to resistance.
Our chance is cure will come with multiple non-cross resistant therapies, challenging current paradigms.
#bcsm
Reposted by Paige
When @breastcancerdoc.bsky.social & I are unintentionally matching at our poster on T-DXd in pts with HER2-low lobular MBC. PFS 7.2m in total cohort, shorter in those with PIK3CA/AKT/PTEN muts & trend toward longer in HER2mut. More research needed in lobular BC!
December 13, 2024 at 2:09 PM
When @breastcancerdoc.bsky.social & I are unintentionally matching at our poster on T-DXd in pts with HER2-low lobular MBC. PFS 7.2m in total cohort, shorter in those with PIK3CA/AKT/PTEN muts & trend toward longer in HER2mut. More research needed in lobular BC!
Reposted by Paige
“ChatGPT can be used for more than college students cheating on essays” Dr Erika Hamilton explains how Sarah Cannon uses this to match patients to trials. #SABCS24
December 12, 2024 at 9:26 PM
“ChatGPT can be used for more than college students cheating on essays” Dr Erika Hamilton explains how Sarah Cannon uses this to match patients to trials. #SABCS24
Reposted by Paige
RLY2608 is a mutant specific PIK3CA inhibitor sparing Wildtype Receptor.
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
December 11, 2024 at 9:42 PM
RLY2608 is a mutant specific PIK3CA inhibitor sparing Wildtype Receptor.
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
Reposted by Paige
🧩How could these puzzle pieces fit? @DrHBurstein suggests one approach ⬇️ #SABCS24 @oncoalert.bsky.social
December 11, 2024 at 3:48 PM
🧩How could these puzzle pieces fit? @DrHBurstein suggests one approach ⬇️ #SABCS24 @oncoalert.bsky.social
Reposted by Paige
#EMBER3 results presented @sabcs.bsky.social #SABCS24 by @breastcancerdoc.bsky.social Main take aways: 1) Imlunestrant ⬆️ PFS > SOC in 1L, ESR1 mut, mER+ BC 2) Imlunestrant + abemaciclib ⬆️ PFS in 1L mER+ BC irrespective of ESR1 or PIK3CA mut 3) Imlunestrant ⬇️ CNS progression 4) OS immature #bcsm
December 11, 2024 at 3:43 PM
#EMBER3 results presented @sabcs.bsky.social #SABCS24 by @breastcancerdoc.bsky.social Main take aways: 1) Imlunestrant ⬆️ PFS > SOC in 1L, ESR1 mut, mER+ BC 2) Imlunestrant + abemaciclib ⬆️ PFS in 1L mER+ BC irrespective of ESR1 or PIK3CA mut 3) Imlunestrant ⬇️ CNS progression 4) OS immature #bcsm
Such important information. But what about in the MBC setting with ER+ disease. Especially with ILC that loves to wonder around the pelvic area.
Great info with a few caveats imho:
- clinicians must cover the sexual & vaginal side effects of all treatments, especially endocrine therapy, before treatment begins
- vaginal estrogen is not contraindicated after breast cancer. Full stop.
- if pain is present, a pelvic exam is essential
#sabcs24
- clinicians must cover the sexual & vaginal side effects of all treatments, especially endocrine therapy, before treatment begins
- vaginal estrogen is not contraindicated after breast cancer. Full stop.
- if pain is present, a pelvic exam is essential
#sabcs24
#SABCS24 #bcsm #OncSky
We need to ask all patients on endocrine therapy for #breastcancer about vaginal dryness & sexual dysfunction. Here’s a useful stepwise approach to managing these issues from
@JenniShengMD. #MedSky
@oncoalert.bsky.social
We need to ask all patients on endocrine therapy for #breastcancer about vaginal dryness & sexual dysfunction. Here’s a useful stepwise approach to managing these issues from
@JenniShengMD. #MedSky
@oncoalert.bsky.social
December 11, 2024 at 1:56 PM
Such important information. But what about in the MBC setting with ER+ disease. Especially with ILC that loves to wonder around the pelvic area.
Reposted by Paige
"For both patients and providers, prior authorization can feel like an unfair game they are designed to lose."
Honored to work w/ Dr @nathangray.bsky.social on a graphic op-ed out now @usatoday.com on how #PriorAuth can leave some patients literally dying in pain.
www.usatoday.com/story/opinio...
Honored to work w/ Dr @nathangray.bsky.social on a graphic op-ed out now @usatoday.com on how #PriorAuth can leave some patients literally dying in pain.
www.usatoday.com/story/opinio...
For patients and doctors, insurance prior authorization can be a dangerous game | Opinion
Doctors trying to get patients necessary drugs and procedures stymied by health insurance prior authorization. It's not a game. It's life and death.
www.usatoday.com
December 8, 2024 at 2:49 PM
"For both patients and providers, prior authorization can feel like an unfair game they are designed to lose."
Honored to work w/ Dr @nathangray.bsky.social on a graphic op-ed out now @usatoday.com on how #PriorAuth can leave some patients literally dying in pain.
www.usatoday.com/story/opinio...
Honored to work w/ Dr @nathangray.bsky.social on a graphic op-ed out now @usatoday.com on how #PriorAuth can leave some patients literally dying in pain.
www.usatoday.com/story/opinio...
Reposted by Paige
Exciting update to our #lobular breast cancer work with DNA repair and PARP inhibition, ahead of @sabcs.bsky.social next week! #oncosky #bcsm
www.biorxiv.org/content/10.1...
Despite lacking "BRCA-like" mutations and features, we find ILC models are sensitive to PARPi in vivo. Why? 🧵 1/n
www.biorxiv.org/content/10.1...
Despite lacking "BRCA-like" mutations and features, we find ILC models are sensitive to PARPi in vivo. Why? 🧵 1/n
Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breast
Invasive lobular carcinoma of the breast (ILC) are typically estrogen receptor α (ER)-positive and present with biomarkers of anti-estrogen sensitive disease, yet patients with ILC face uniquely poor ...
www.biorxiv.org
December 6, 2024 at 9:47 PM
Exciting update to our #lobular breast cancer work with DNA repair and PARP inhibition, ahead of @sabcs.bsky.social next week! #oncosky #bcsm
www.biorxiv.org/content/10.1...
Despite lacking "BRCA-like" mutations and features, we find ILC models are sensitive to PARPi in vivo. Why? 🧵 1/n
www.biorxiv.org/content/10.1...
Despite lacking "BRCA-like" mutations and features, we find ILC models are sensitive to PARPi in vivo. Why? 🧵 1/n
Reposted by Paige
Hey #oncosky and 🧪 friends - so glad you're here!
A quick (re)intro to the Sikora Lab (www.sikoralab.com):
We study:
1) #lobular breast cancer and its complicated relationship w estrogen.
2) gyn / ovarian cancer, metabolic parallels w #lobular, and genetic links to health disparities.
1/n
A quick (re)intro to the Sikora Lab (www.sikoralab.com):
We study:
1) #lobular breast cancer and its complicated relationship w estrogen.
2) gyn / ovarian cancer, metabolic parallels w #lobular, and genetic links to health disparities.
1/n
Home
welcome to the sikora lab
www.sikoralab.com
November 25, 2024 at 5:04 PM
Hey #oncosky and 🧪 friends - so glad you're here!
A quick (re)intro to the Sikora Lab (www.sikoralab.com):
We study:
1) #lobular breast cancer and its complicated relationship w estrogen.
2) gyn / ovarian cancer, metabolic parallels w #lobular, and genetic links to health disparities.
1/n
A quick (re)intro to the Sikora Lab (www.sikoralab.com):
We study:
1) #lobular breast cancer and its complicated relationship w estrogen.
2) gyn / ovarian cancer, metabolic parallels w #lobular, and genetic links to health disparities.
1/n
Reposted by Paige
More #thinkibc inflammatory breast cancer community on 🦋🦋 #bcsm Now the incomparable Dr. Lim!! #oncsky @talkibc.bsky.social @mdanderson.bsky.social @debeblab.bsky.social 🎉🎉
November 23, 2024 at 7:44 PM
More #thinkibc inflammatory breast cancer community on 🦋🦋 #bcsm Now the incomparable Dr. Lim!! #oncsky @talkibc.bsky.social @mdanderson.bsky.social @debeblab.bsky.social 🎉🎉